# A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).

> **NCT04319367** · PHASE2 · RECRUITING · sponsor: **Imperial College London** · enrollment: 72 (estimated)

## Conditions studied

- HIV/AIDS and Infections

## Interventions

- **DRUG:** Investigational Medicinal Product

## Key facts

- **NCT ID:** NCT04319367
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-17
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2024-04-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04319367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04319367, "A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04319367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*